US approves blood plasma use to treat Covid patients

US approves blood plasma use to treat Covid patients

The US Food and Drug Administration (FDA) has given emergency authorisation to use plasma to treat Covid patients.

The technique uses antibody-rich blood plasma from people who’ve recovered from the disease and has already been applied to 70,000 people in the US – in trials or for the gravely ill.
The FDA says initial trials indicate it is safe, although more are needed to prove effectiveness.

Several experts have questioned the robustness of studies into its use.

The announcement came a day after President Donald Trump accused the FDA of impeding the rollout of vaccines and therapeutics for political reasons, and on the eve of the Republican National Convention, where Mr Trump will launch his campaign to win a second term in the White House.

“This is what I’ve been looking forward to doing for a long time,” the president told reporters on Sunday.
“I’m pleased to make a truly historic announcement in our battle against the China virus that will save countless lives.”
Mr Trump described the procedure as a powerful therapy, as he appealed to Americans to come forward to donate plasma if they had recovered from Covid-19.

More than 176,000 people have died from coronavirus since the start of the outbreak in the United States, according to a tally by Johns Hopkins University. Nearly 5.7 million cases have also been confirmed nationwide. The country has had more confirmed cases and deaths than anywhere else in the world.

The FDA had already approved the use of plasma transfusions on coronavirus patients under certain conditions.
It has now given the treatment “emergency use authorisation”, rather than full approval, saying that early research suggests blood plasma can decrease mortality and improve patient health if it is administered within the first three days of admittance to hospital. However, more trials are needed to prove its effectiveness.

COMMENTS

WORDPRESS: 0
DISQUS: 0